BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 36506255)

  • 1. Differentiating Oncocytic Renal Tumors from Chromophobe Renal Cell Carcinoma: Comparison of Peak Early-phase Enhancement Ratio to Clinical Risk Factors and Rater Predictions.
    Patel HD; Huai K; Elliott N; Thorson DL; Rac G; Picken MM; Quek ML; Bova D; Gupta GN
    Eur Urol Open Sci; 2022 Dec; 46():8-14. PubMed ID: 36506255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and Validation of Radiographic Enhancement for Reliable Differentiation of CD117(+) Benign Renal Oncocytoma and Chromophobe Renal Cell Carcinoma.
    Amin J; Xu B; Badkhshan S; Creighton TT; Abbotoy D; Murekeyisoni C; Attwood KM; Schwaab T; Hendler C; Petroziello M; Roche CL; Kauffman EC
    Clin Cancer Res; 2018 Aug; 24(16):3898-3907. PubMed ID: 29752278
    [No Abstract]   [Full Text] [Related]  

  • 3. Aorta-Lesion-Attenuation-Difference (ALAD) on contrast-enhanced CT: a potential imaging biomarker for differentiating malignant from benign oncocytic neoplasms.
    Dhyani M; Grajo JR; Rodriguez D; Chen Z; Feldman A; Tambouret R; Gervais DA; Arellano RS; Hahn PF; Samir AE
    Abdom Radiol (NY); 2017 Jun; 42(6):1734-1743. PubMed ID: 28197683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic utility of vimentin, CD117, cytokeratin-7 and caveolin-1 in differentiation between clear cell renal cell carcinoma, chromophobe renal cell carcinoma and oncocytoma.
    El-Shorbagy SH; Alshenawy HA
    J Microsc Ultrastruct; 2017; 5(2):90-96. PubMed ID: 30023241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of the Aortic-Lesion-Attenuation-Difference (ALAD) and Peak Early-Phase Enhancement Ratio (PEER) to differentiate benign from malignant renal masses.
    Kahn AE; Lomax SJ; Bajalia EM; Ball CT; Thiel DD
    Can J Urol; 2020 Aug; 27(4):10278-10284. PubMed ID: 32861252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of specific contrast-enhanced CT regions of interest to differentiate renal oncocytomas from small clear cell and chromophobe renal cell carcinomas.
    Qu JY; Jiang H; Wang XF; Song XH; Hao CJ
    Diagn Interv Radiol; 2022 Nov; 28(6):555-562. PubMed ID: 36550755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of computed tomography findings between renal oncocytomas and chromophobe renal cell carcinomas.
    Choi JH; Kim JW; Lee JY; Han WK; Rha KH; Choi YD; Hong SJ; Yoon YE
    Korean J Urol; 2015 Oct; 56(10):695-702. PubMed ID: 26495070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using Aorta-Lesion-Attenuation Difference on Preoperative Contrast-enhanced Computed Tomography Scan to Differentiate Between Malignant and Benign Renal Tumors.
    Grajo JR; Terry RS; Ruoss J; Noennig BJ; Pavlinec JG; Bozorgmehri S; Crispen PL; Su LM
    Urology; 2019 Mar; 125():123-130. PubMed ID: 30552939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DOG1, cyclin D1, CK7, CD117 and vimentin are useful immunohistochemical markers in distinguishing chromophobe renal cell carcinoma from clear cell renal cell carcinoma and renal oncocytoma.
    Zhao W; Tian B; Wu C; Peng Y; Wang H; Gu WL; Gao FH
    Pathol Res Pract; 2015 Apr; 211(4):303-7. PubMed ID: 25596994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a DNA Methylation-Based Diagnostic Signature to Distinguish Benign Oncocytoma From Renal Cell Carcinoma.
    Brennan K; Metzner TJ; Kao CS; Massie CE; Stewart GD; Haile RW; Brooks JD; Hitchins MP; Leppert JT; Gevaert O
    JCO Precis Oncol; 2020; 4():. PubMed ID: 33015531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Automated differentiation of benign renal oncocytoma and chromophobe renal cell carcinoma on computed tomography using deep learning.
    Baghdadi A; Aldhaam NA; Elsayed AS; Hussein AA; Cavuoto LA; Kauffman E; Guru KA
    BJU Int; 2020 Apr; 125(4):553-560. PubMed ID: 31901213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sporadic oncocytic tumors with features intermediate between oncocytoma and chromophobe renal cell carcinoma: comprehensive clinicopathological and genomic profiling.
    Liu YJ; Ussakli C; Antic T; Liu Y; Wu Y; True L; Tretiakova MS
    Hum Pathol; 2020 Oct; 104():18-29. PubMed ID: 32673684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of aorta-lesion-attenuation difference on preoperative contrast-enhanced computed tomography scan to differentiate between malignant and benign oncocytic renal tumors.
    Grajo JR; Batra NV; Bozorgmehri S; Magnelli LL; Pavlinec J; O'Malley P; Su LM; Crispen PL
    Abdom Radiol (NY); 2021 Jul; 46(7):3269-3279. PubMed ID: 33665734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amylase α-1A (AMY1A): a novel immunohistochemical marker to differentiate chromophobe renal cell carcinoma from benign oncocytoma.
    Jain S; Roy S; Amin M; Acquafondata M; Yin M; Laframboise W; Bastacky S; Pantanowitz L; Dhir R; Parwani A
    Am J Surg Pathol; 2013 Dec; 37(12):1824-30. PubMed ID: 24225843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring Multiphoton Microscopy as a Novel Tool to Differentiate Chromophobe Renal Cell Carcinoma From Oncocytoma in Fixed Tissue Sections.
    Jain M; Robinson BD; Wu B; Khani F; Mukherjee S
    Arch Pathol Lab Med; 2018 Mar; 142(3):383-390. PubMed ID: 29219617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative computer-aided diagnostic algorithm for automated detection of peak lesion attenuation in differentiating clear cell from papillary and chromophobe renal cell carcinoma, oncocytoma, and fat-poor angiomyolipoma on multiphasic multidetector computed tomography.
    Coy H; Young JR; Douek ML; Brown MS; Sayre J; Raman SS
    Abdom Radiol (NY); 2017 Jul; 42(7):1919-1928. PubMed ID: 28280876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness Analysis of
    Su ZT; Patel HD; Huang MM; Meyer AR; Pavlovich CP; Pierorazio PM; Javadi MS; Allaf ME; Rowe SP; Gorin MA
    Eur Urol Focus; 2021 Jul; 7(4):827-834. PubMed ID: 32115400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Oncocytoma versus chromophobe renal cell carcinoma: Is there something in between?].
    Lüders C; Kristiansen G
    Pathologe; 2016 Mar; 37(2):153-8. PubMed ID: 26925847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Next-generation RNA Sequencing-based Biomarker Characterization of Chromophobe Renal Cell Carcinoma and Related Oncocytic Neoplasms.
    Skala SL; Wang X; Zhang Y; Mannan R; Wang L; Narayanan SP; Vats P; Su F; Chen J; Cao X; Siddiqui J; Argani P; Cieślik MP; Giordano TJ; Chinnaiyan AM; Dhanasekaran SM; Mehra R
    Eur Urol; 2020 Jul; 78(1):63-74. PubMed ID: 32299640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of computed tomography features in the differential diagnosis of chromophobe renal cell carcinoma from oncocytoma and angiomyolipoma without visible fat.
    Zhou C; Ban X; Lv J; Cheng L; Xu J; Shen X
    Quant Imaging Med Surg; 2022 Apr; 12(4):2332-2343. PubMed ID: 35371954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.